Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Over 250 Institutions participate in the effort of sharing data on the efficacy of antimalarial drugs, which involves standardising and re-analysing data. Bringing all this data together creates new evidence that can be translated into policy practice, offering new therapeutic options for particular populations.

Q: What is the WorldWide Antimalarial Resistance Network and what are its aims?

Philippe Guérin: The WorldWide Antimalarial Resistance Network is a scientifically independent network of scientists who are working together to assemble data on the efficacy of antimalarials.

We started in 2009 and we are engaging the research community to bring together all data which assess the efficacy of drugs, specifically antimalarials. This allows us to gain power in the way we are interpreting all of this data and this is already also creating strong evidence that can be translated into practice.

Q: What kind of work does the network do?

PG: We are working with the research community and as of today we have more than 250 institutions participating in this effort. They are sharing data in the network and we are collating all this information, putting it into common repositories, standardising the data and reanalysing all this information: going back to the clinical trial data and individual patient data and trying to make sense of all of that.

This is gaining power in the evidence that we can draw from this pooled analysis, and also generating all sorts of collaborations between different partners working together. Together, these 250 groups are almost the majority of all the groups working on antimalarials in the world, and we have assembled more than two-thirds of the clinical data on artemisinin combination therapy which has been generated in the last 15 years.

Q: What does your own line of research focus on?

PG: Currently we are trying to answer two different scientific questions. We are working on malaria and malnutrition for instance. We are gathering data on children between six months and five years who have experienced malaria and who are also either chronically or acutely malnourished: we are trying to understand if the drugs that we are normally using for children are working as well. We already know that this is not the case, and so the point would be eventually to draw evidence about what could be an optimised drug or treatment that could be adapted for a child with this kind of co-morbidities.

We are also working with laboratories to try to enhance the way the quality of the data and the way people are standardising their data can be improved. We are working with 60 laboratories in 28 countries, providing external quality assurance and this is making people work together. This network is an central point to facilitate that.

Q: What are the most important lines of research that have emerged over the last 5-10 years?

PG: In our space there is an engagement and a movement into data sharing. There is a lot of push in data sharing from funders and policy makers, journals, etc.

In the space of infectious diseases, I think we have pioneered a data sharing platform in malaria, and gathering all of these groups working together. Usually scientists compete: here they are working collectively for the same goal! We are translating the swish and the movement of big data into reality, addressing all the sensibilities around that and trying to ensure that the investigator gains in that experience, and that we are all gaining by providing evidence that can be translated into practice.

Q: Why does this line of work matter and why should we put money in to it?

PG: Bringing all this data together creates new evidence. There are fantastic groups working in the field of antimalarial efficacy and testing drugs. They are generating great evidence, but none of these groups can answer some particular questions: it is only by assembling all this data together that we are able to do so. Therefore it is complementary to the work done by our colleagues and it is also a nice additional outcome of their work that we are managing to generate by this data sharing effort and data sharing platform.

Q: How does your work fit into translational medicine within the department?

PG: The kind of evidence from the meta-analysis that we are doing generate new guidance and new evidence that can be translated into policy practice. Some of the work that we have done has been taken on board by expert committee, and the World Health Organisation guidelines are using this kind of data to propose new therapeutic options for particular population. This is a great outcome of direct consequences of our work into practice for physicians in the field treating particular populations.

Philippe Guérin


Professor Philippe Guérin is Director of the WorldWide Antimalarial Resistance Network (WWARN). The best lines of defence against malaria are avoidance of mosquito bites and effective drug therapy. WWARN tracks the emergence of antimalarial drug resistance to ensure that anyone affected by malaria receives effective and safe drug treatment.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.